Pegvisomant in acromegaly: a multicenter real-life study in Argentina.

Natalia Ximena Garcia Basavilbaso Maria Carolina Ballarino Darío Bruera Oscar D Bruno Alberto B Chervin Karina Danilowicz Patricia Fainstein-Day Silvina Gabriela Fidalgo Adriana Frigeri Mariela Glerean Rodolfo Guelman Gabriel Isaac Debora Adela Katz Pablo Knoblovits Fabiana Librandi Monica López Montes Maria Susana Mallea-Gil Marcos Manavela Paula Mereshian Daniel Moncet Analia Pignatta Amelia Rogozinski Laura R Sago Marisa Servidio Monica Spezzi Graciela Stalldecker Julieta Tkatch Nicolas Marcelo Vitale Mirtha Guitelman

Published in: Archives of endocrinology and metabolism (2019)

this long term experience indicates PEGV treatment was highly effective and safe in our series of Argentine patients with acromegaly refractory to standard therapies. Arch Endocrinol Metab. 2019;63(4):320-7.

Keyphrases

growth hormone
clinical trial
combination therapy
double blind